Basic Information
| LncRNA/CircRNA Name | lnc-DILC |
| Synonyms | TFDP1, DILC, DP1, DRTF1, Dp-1 |
| Region | GRCh38_13:113584721-113641470 |
| Ensemble | ENSG00000198176 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | liver cancer |
| ICD-0-3 | C22.0 |
| Methods | Microarray, Luciferase reporter assay etc. |
| Sample | HCC tissues |
| Expression Pattern | down-regulated |
| Function Description | Depletion of lnc-DILC markedly enhanced LCSC expansion and facilitated HCC initiation and progression, whereas ectopic expression of lnc-DILC dramatically inhibited LCSC expansion. Mechanistically, lnc-DILC inhibited the autocrine IL-6/STAT3 signaling. The putative binding locus of lnc-DILC within IL-6 promoter was confirmed by pull down assay. Consistently, the oligoribonucleotide mimics and an oligodeoxynucleotide decoy of lnc-DILC abrogated the effects on IL-6 transcription, STAT3 activation and LCSC expansion triggered by lnc-DILC depletion and lnc-DILC overexpression. Moreover, our data suggested that lnc-DILC mediated the crosstalk between TNF-a/NF-kB signaling and IL-6/STAT3 cascade. Clinical investigation demonstrated the reduction of lnc-DILC in patient HCCs, and suggested the correlation between lnc-DILC levels and IL-6, EpCAM or CD24 expression. Decreased lnc-DILC expression in HCCs predicts early recurrence and short survival of patients, highlighting its prognostic value |
| Pubmed ID | 26812074 |
| Year | 2016 |
| Title | Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis |
External Links
| Links for lnc-DILC | GenBank HGNC NONCODE |
| Links for liver cancer | OMIM COSMIC |